•  
  •  
  •  
  •  

2025-12-25 07:06:55

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Deepak Mining Solutions Ltd to acquire 100% in Explosives Manufacturer
  • BharatRohan Airborne Innovations secures DGCA Type Certification for 'Pravir-X6', Advancing Sustainable Farm Mechanization
  • Karnataka HC sets aside IT assessment order with demand of Rs. 779.56 Mn against Aequs Limited
  • Silicon Rental Solutions Ltd receives order from Techfruits Solutions Pvt Ltd
  • Royal Orchid Hotels Strengthens Central India Portfolio with New Signing in Gwalior, Madhya Pradesh

Keywords Selected:  IoT

Research

  • Q2FY22 Result Update - Biocon Ltd - ICICI Direct

IPO News

  • Concord Biotech Limited's IPO to open on Friday, 4th August, 2023, sets price band at ₹705 to ₹741 per Equity Share
  • Windlas Biotech Ltd posts consolidated PAT of Rs. 11.44 crores in Q4FY23
  • Ahmedabad-based Concord Biotech gets SEBI nod for IPO
  • Rare Enterprises and Quadria Capital-backed Concord Biotech files DRHP for IPO

Stock Report

  • Fermenta ranked among India's Best Workplaces™ in Pharmaceuticals, Healthcare & Biotech by Great Place to Work®
  • Biocon Ltd signs out-licensing agreement with Ajanta to market Semaglutide in 26 countries
  • Biocon Biologics Secures Full Global Rights to Biosimilar Adalimumab through Expanded FKB In-Licensing Agreement
  • Kinetic Watts & Volts Joins Hands with Jio Things to Build India's Next-Gen Connected EVs
  • Biocon Ltd receives EIR from USFDA with VAI status for Cranbury facility
  • Biocon Biologics Recognized as Asia IP Elite for 2025 by IAM
  • Biocon Limited launches its Glucagon-like Peptide-1, Liraglutide, in the Netherlands
  • Biocon Biologics Signs Settlement and License Agreement to Commercialize Biosimilar Aflibercept Worldwide
  • Fermenta Board approves INR 110 Crore Capex at Dahej for Plant-based Vitamin D3, Green Chemistry Enzyme, and Vitamin D3 Derivatives
  • Biocon Ltd to integrate Biocon Biologics Ltd to create a Unified Global Biopharmaceutical Leader
  • Cellecor Expands its Smart TV Portfolio with New Jio-Powered QLED Smart TV Series
  • Biocon Biologics Secures Market Entry Date for Denosumab Biosimilars in Europe and Rest of the World
  • Viceroy Hotels Ltd to acquire SLN Terminus Hotels and Resorts Pvt Ltd
  • US FDA Accepts Wockhardt's New Drug Application for Breakthrough Antibiotic Zaynich
  • Juniper Hotels Ltd to submit resolution plan for Gstaad Hotels Pvt Ltd
  • Biocon Biologics' Drug Substance Facility in Bengaluru Classified as Voluntary Action Indicated
  • Biocon Pharma Ltd receives approval from USFDA for its ANDA
  • Kapil Cotex Ltd is now Skybiotech Healthcare Ltd
  • Biocon Biologics Receives Health Canada Approval for Yesintek™ and Yesintek™ I.V., a Biosimilar to Stelara®
  • Coastal Biotech Pvt Ltd receives allocation for Supply of Ethanol to OMC's under Ethanol Blended Petrol Programme
  • Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine
  • Rossari Biotech Ltd Q2 FY2025-26 consolidated PAT increases to Rs. 36.87 crores
  • Biocon Limited updates on GMP inspection by USFDA at its Cranbury, New Jersey facility
  • Panacea Biotec Ltd receives acceptance from CMSS for supply of bOPV

Industry News

  • Semicon startup Netrasemi raises Rs 10 crore in Pre Series A round from Unicorn India Ventures to build Edge AI
  • Samsung Innovation Campus Upskills 3,000 Less-Privileged Students Across India in AI, IoT, Big Data and Coding & Programming

Latest Post

  • Deepak Mining Solutions Ltd to acquire 100% in Explosives Manufacturer
  • BharatRohan Airborne Innovations secures DGCA Type Certification for 'Pravir-X6', Advancing Sustainable Farm Mechanization
  • Karnataka HC sets aside IT assessment order with demand of Rs. 779.56 Mn against Aequs Limited
  • Silicon Rental Solutions Ltd receives order from Techfruits Solutions Pvt Ltd
  • Royal Orchid Hotels Strengthens Central India Portfolio with New Signing in Gwalior, Madhya Pradesh


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024